Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis.

Area of Science:

• Addiction Medicine
• Health Economics
• Pharmacotherapy

Background:

• Opioid dependence is a significant public health issue requiring effective and economically viable treatment options.
• Methadone maintenance therapy (MMT) and buprenorphine maintenance therapy (BMT) are primary pharmacotherapies for opioid use disorder.
• Third-party payers require evidence on the cost-effectiveness of different treatment modalities.

Purpose of the Study:

• To compare the cost-effectiveness of clinic-based MMT versus office-based BMT for opioid-dependent patients.
• To evaluate treatment retention and opioid abuse-free weeks as key effectiveness outcomes.
• To analyze the economic impact from a third-party payer perspective in the U.S.

Main Methods:

• A Markov cost-effectiveness model was utilized.
• A hypothetical cohort of 1000 adult opioid-dependent patients was simulated over a 1-year period.
• Probabilities were derived from randomized clinical trials comparing MMT and BMT, with costs including drugs, administration, and therapy.

Main Results:

• MMT demonstrated higher retention rates (20.3% vs. 15.9%) and opioid abuse-free weeks (9.2 vs. 9.1) compared to BMT.
• The incremental cost-effectiveness ratio (ICER) for MMT was $10,437 per patient retained and $8,515 per opioid abuse-free week gained.
• Sensitivity analyses indicated that MMT costs significantly impact retention, while dropout probability influences abuse-free weeks.

Conclusions:

• Clinic-based methadone maintenance therapy (MMT) is a cost-effective treatment option compared to office-based buprenorphine maintenance therapy (BMT) for opioid dependence.
• MMT offers superior effectiveness in terms of patient retention and reduction of opioid abuse.
• Healthcare decision-makers should weigh these cost-effectiveness findings alongside individual patient characteristics when determining coverage policies.